CL2020002939A1 - Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas - Google Patents

Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas

Info

Publication number
CL2020002939A1
CL2020002939A1 CL2020002939A CL2020002939A CL2020002939A1 CL 2020002939 A1 CL2020002939 A1 CL 2020002939A1 CL 2020002939 A CL2020002939 A CL 2020002939A CL 2020002939 A CL2020002939 A CL 2020002939A CL 2020002939 A1 CL2020002939 A1 CL 2020002939A1
Authority
CL
Chile
Prior art keywords
treatment
thiazol
sensitization
diseases associated
nerve fibers
Prior art date
Application number
CL2020002939A
Other languages
English (en)
Inventor
Christian Friedrich
Isabella Gashaw
Damian Brockschnieder
Oliver Martin Fischer
Original Assignee
Bayer Ag
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag, Bayer Pharma AG filed Critical Bayer Ag
Publication of CL2020002939A1 publication Critical patent/CL2020002939A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La presente invención se refiere al uso de compuestos de benzamida sustituida con 1,3-tiazol-2-ilo de la fórmula general (I) tal como se ha descripto y definido en la presente, a composiciones farmacéuticas y combinaciones que comprenden esos compuestos para el tratamiento o la profilaxis de enfermedades asociadas a la sensibilización de fibras nerviosas, en particular para el tratamiento y la profilaxis de la Tos Crónica (TC), la Fibrosis Pulmonar Idiopática (FPI), la Enfermedad Pulmonar Obstructiva Crónica (EPOC), y el asma.
CL2020002939A 2018-05-15 2020-11-12 Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas CL2020002939A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP18172409 2018-05-15

Publications (1)

Publication Number Publication Date
CL2020002939A1 true CL2020002939A1 (es) 2021-03-05

Family

ID=62186254

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002939A CL2020002939A1 (es) 2018-05-15 2020-11-12 Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas

Country Status (16)

Country Link
US (1) US20210220358A1 (es)
EP (1) EP3793554A1 (es)
JP (1) JP2021523919A (es)
KR (1) KR20210009341A (es)
CN (1) CN112334132A (es)
AU (1) AU2019269049A1 (es)
BR (1) BR112020022553A2 (es)
CA (1) CA3100099A1 (es)
CL (1) CL2020002939A1 (es)
EA (1) EA202092678A1 (es)
JO (1) JOP20200286A1 (es)
MA (1) MA52618A (es)
MX (1) MX2020012202A (es)
SG (1) SG11202011010YA (es)
TW (1) TWI780329B (es)
WO (1) WO2019219674A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3230281B1 (en) 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
ES2963702T3 (es) 2018-10-05 2024-04-01 Shionogi & Co Medicina para tratar la tos crónica
GB201908219D0 (en) 2019-06-10 2019-07-24 Axalbion Sa Therapeutic use of a compound
EP3757103A1 (en) * 2019-06-27 2020-12-30 Bayer AG Analogues of 3-(5-methyl-1,3-thiazol-2-yl)-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}benzamide for the treatment of neurogenic diseases
CN113082023B (zh) * 2019-12-23 2024-03-01 武汉朗来科技发展有限公司 P2x3抑制剂和p2x4抑制剂的药物组合及其应用
WO2021238834A1 (zh) * 2020-05-25 2021-12-02 中国医药研究开发中心有限公司 芳甲酰胺类化合物及其制备方法和医药用途
CN114315818B (zh) * 2020-09-30 2026-04-28 武汉人福创新药物研发中心有限公司 苯甲酰胺类化合物及其用途
WO2022253943A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Crystalline forms of 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoro-methyl)pyrimidin-5-yl]ethyl}-benzamide
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
CA2715835C (en) * 2008-02-29 2017-03-21 Renovis, Inc. Amide compounds, compositions and uses thereof
AU2014308606B2 (en) * 2013-08-23 2017-08-03 Afferent Pharmaceuticals Inc. Diaminopyrimidine P2X3 and P2X 2/3 receptor modulators for treatment of acute, sub-acute or chronic cough
US10183937B2 (en) * 2014-12-09 2019-01-22 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
EP3230281B1 (en) * 2014-12-09 2021-05-26 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides
DK3355889T3 (da) * 2015-09-29 2023-05-15 Afferent Pharmaceuticals Inc Diaminopyrimidin-p2x3- og p2x2/3-receptormodulatorer til anvendelse i behandling af hoste
EP3793553A1 (en) * 2018-05-15 2021-03-24 Bayer Aktiengesellschaft 1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization

Also Published As

Publication number Publication date
MA52618A (fr) 2021-04-21
MX2020012202A (es) 2021-01-29
US20210220358A1 (en) 2021-07-22
BR112020022553A2 (pt) 2021-02-02
CA3100099A1 (en) 2019-11-21
TWI780329B (zh) 2022-10-11
TW201946924A (zh) 2019-12-16
JP2021523919A (ja) 2021-09-09
CN112334132A (zh) 2021-02-05
AU2019269049A1 (en) 2020-11-26
EP3793554A1 (en) 2021-03-24
KR20210009341A (ko) 2021-01-26
WO2019219674A1 (en) 2019-11-21
JOP20200286A1 (ar) 2020-11-09
EA202092678A1 (ru) 2021-04-12
SG11202011010YA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
CL2020002939A1 (es) Uso de benzamidas sustituidas con 1,3-tiazol-2-ilo para el tratamiento de enfermedades asociadas a la sensibilización de las fibras nerviosas
CL2021003165A1 (es) Derivados de aminoquinazolina como inhibidores del purinoreceptor 3 de p2x (p2x3)
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
CO2019008986A2 (es) Derivados de tirosinamida como inhibidores de rho-quinasa
UY29840A1 (es) Compuestos de pirimidina amida como inhibidores de pgds
NI201500142A (es) Derivados de 3-acetilamino-1 (fenil-heteroaril-aminocarbonil o fenil-heteroaril-carbonilamino) benceno para el tratamiento de desordenes hiperproliferativos.
JOP20150301B1 (ar) بنزاميدات مستبدلة مع 3،1-ثيازول-2- يل
MX2019005009A (es) 1,2,4-triazolonas 2,4,5-trisustituidas.
PA8774101A1 (es) Compuesto de pirmidina
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112014003382A2 (pt) análogos de (e)-n'-(1-feniletilideno)benzo-hidrazida substituída como inibidores de histona desmetilase
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
UY32938A (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
MX2021015853A (es) Analogos de 3-(5-metil-1,3-tiazol-2-il)-n-{(1r)-1-[2-(trifluor-met il)pirimidin-5-il]etil}benzamida.
MX2022013014A (es) Nuevas formas cristalinas de trifenatato de vilanterol y procedimientos para su preparacion.
MX2021014116A (es) Derivados de piridopirimidinas como inhibidores del purinoreceptor 3 de p2x (p2x3).
BR112023004612A2 (pt) Derivados de 2-(3-piridin-2-il-4-quinolin-4-il-pirazol-1-il)-acetamida como inibidores de receptor i de fator-beta de crescimento transformador/alk5
PH12020500204A1 (en) Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic disease
BR112022002772A2 (pt) Formas cristalinas de análogos de quinolina e sais dos mesmos, composições e seus métodos para uso
MX366353B (es) Agentes terapeuticos para uso en la profilaxis y/o tratamiento de trastornos de movimiento hipercinetico.
MX2021015553A (es) Inhibidores de arginasa novedosos.
UY36983A (es) Pirazolopiridinaminas sustituidas
PT110896A (pt) Forma amorfa de trifenatato de vilanterol e processos para a preparação da mesma
UY30988A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
MX2018010008A (es) Derivado de piperidina y sus métodos de uso.